New additions to Medtronic's product range
This article was originally published in Clinica
Executive Summary
Medtronic has received US FDA clearance to market its Sprint 6932 ICD leads and has launched a cerebral catheter. Introduced in Europe in May, the 6932 is the first of a new family of defibrillator leads for active-can devices that feature multiple lumens and narrower conductors. The 7.8F lead uses Medtronic's tined, steroid-eluting electrode. Clinical trials of the 6942, a triple-lumen lead for defibrillating both the right ventricle and the superior vena cava, began in Europe in July. An active fixation version (6943) is expected to enter trials in the near future.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.